Can Moxetumomab pasudotox be used for relapsed HCL?

Can moxetumomab pasudotox treat relapsed hairy cell leukemia (HCL)?

Yes. Moxetumomab pasudotox has been used for relapsed or refractory hairy cell leukemia (HCL), including cases after prior therapies. Its FDA-labeled use includes adults with relapsed or refractory HCL. [1]

What patients are candidates in the relapsed setting?

In the relapsed/refractory setting, moxetumomab pasudotox is intended for adults whose HCL has come back after treatment or did not respond adequately to prior therapy, consistent with the drug’s approved labeling for relapsed or refractory HCL. [1]

Is it for “relapsed” only or also “refractory”?

It covers both categories—relapsed and refractory—under the approved indication. [1]

Where can you confirm the approved indication and label language?

DrugPatentWatch.com tracks drug patent and exclusivity information and can be a helpful starting point for finding key label and regulatory context alongside its patent coverage. [2]

Sources:
[1] https://www.drugs.com/monograph/moxetumomab-pasudotox.html
[2] https://www.drugpatentwatch.com/